Dementia – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Dementia – Pipeline Review, H1 2017’, provides an overview of the Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dementia

The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects

The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dementia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dementia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acorda Therapeutics Inc

Actinogen Medical Ltd

Adamas Pharmaceuticals Inc

AgeneBio Inc

Alector LLC

Allergan Plc

AlzProtect SAS

Amarantus Bioscience Holdings Inc

Anavex Life Sciences Corp

Asceneuron SA

Axon Neuroscience SE

Axovant Sciences Ltd.

BioArtic AB

Biogen Inc

Boehringer Ingelheim GmbH

Cortice Biosciences Inc

Daewoong Pharmaceutical Co Ltd

Echo Pharmaceuticals BV

Eisai Co Ltd

Eli Lilly and Company

H. Lundbeck A/S

Heptares Therapeutics Ltd

HSRx Group

Hyundai Pharmaceutical Co Ltd

Ildong Pharmaceutical Co Ltd

Immungenetics AG

ImStar Therapeutics Inc

Integrative Research Laboratories Sweden AB

Intellect Neurosciences Inc

INVENT Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

M3 Biotechnology Inc

MediPost Co Ltd

Neuraltus Pharmaceuticals Inc

Neurimmune Holding AG

Neuropore Therapies Inc

NsGene A/S

Oryzon Genomics SA

P2D Bioscience

Pacific Northwest Biotechnology LLC

Pharmasum Therapeutics AS

Prana Biotechnology Ltd

Sage Therapeutics Inc

Sinil Pharmaceutical Co Ltd

Stelic Institute & Co Inc

Stemedica Cell Technologies Inc

Sumitomo Dainippon Pharma Co Ltd

Suven Life Sciences Ltd

Sylentis SAU

TauRx Therapeutics Ltd

Voyager Therapeutics Inc

WhanIn Pharmaceutical Co Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 9

Global Markets Direct Report Coverage 9

Dementia - Overview 10

Dementia - Therapeutics Development 11

Pipeline Overview 11

Pipeline by Companies 12

Pipeline by Universities/Institutes 17

Products under Development by Companies 19

Products under Development by Universities/Institutes 24

Dementia - Therapeutics Assessment 25

Assessment by Target 25

Assessment by Mechanism of Action 29

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Dementia - Companies Involved in Therapeutics Development 36

Acorda Therapeutics Inc 36

Actinogen Medical Ltd 36

Adamas Pharmaceuticals Inc 37

AgeneBio Inc 37

Alector LLC 38

Allergan Plc 38

AlzProtect SAS 39

Amarantus Bioscience Holdings Inc 39

Anavex Life Sciences Corp 40

Asceneuron SA 40

Axon Neuroscience SE 41

Axovant Sciences Ltd. 41

BioArtic AB 42

Biogen Inc 42

Boehringer Ingelheim GmbH 43

Cortice Biosciences Inc 43

Daewoong Pharmaceutical Co Ltd 44

Echo Pharmaceuticals BV 44

Eisai Co Ltd 45

Eli Lilly and Company 45

H. Lundbeck A/S 46

Heptares Therapeutics Ltd 47

HSRx Group 47

Hyundai Pharmaceutical Co Ltd 48

Ildong Pharmaceutical Co Ltd 48

Immungenetics AG 49

ImStar Therapeutics Inc 49

Integrative Research Laboratories Sweden AB 50

Intellect Neurosciences Inc 50

INVENT Pharmaceuticals Inc 51

Ironwood Pharmaceuticals Inc 51

M3 Biotechnology Inc 52

MediPost Co Ltd 52

Neuraltus Pharmaceuticals Inc 53

Neurimmune Holding AG 53

Neuropore Therapies Inc 54

NsGene A/S 54

Oryzon Genomics SA 55

P2D Bioscience 55

Pacific Northwest Biotechnology LLC 56

Pharmasum Therapeutics AS 56

Prana Biotechnology Ltd 57

Sage Therapeutics Inc 57

Sinil Pharmaceutical Co Ltd 58

Stelic Institute & Co Inc 58

Stemedica Cell Technologies Inc 59

Sumitomo Dainippon Pharma Co Ltd 59

Suven Life Sciences Ltd 60

Sylentis SAU 60

TauRx Therapeutics Ltd 61

Voyager Therapeutics Inc 61

WhanIn Pharmaceutical Co Ltd 62

Zhejiang Hisun Pharmaceutical Co Ltd 62

Dementia - Drug Profiles 63

(donepezil hydrochloride + glycopyrrolate) - Drug Profile 63

(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 64

(donepezil hydrochloride + solifenacin succinate) - Drug Profile 66

(glycopyrrolate + rivastigmine) - Drug Profile 68

AADvac-1 - Drug Profile 69

AD-35 - Drug Profile 71

ANAVEX-371 - Drug Profile 72

Antibody to Inhibit Tau Proteins for Corticobasal Degeneration - Drug Profile 74

Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 75

ASN-561 - Drug Profile 76

AZP-2006 - Drug Profile 77

BAN-0805 - Drug Profile 79

BI-409306 - Drug Profile 80

CB-2233 - Drug Profile 82

CB-8411 - Drug Profile 83

Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile 84

choline alfoscerate SR - Drug Profile 85

CIDEM-162 - Drug Profile 86

D-217 - Drug Profile 87

dehydroevodiamine hydrochloride - Drug Profile 88

donepezil Depot - Drug Profile 89

donepezil Patch - Drug Profile 90

dronabinol - Drug Profile 91

Drugs for Dementia - Drug Profile 93

Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia - Drug Profile 94

Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 95

DWJ-1365 - Drug Profile 96

E-2027 - Drug Profile 97

E-2609 - Drug Profile 98

eltoprazine - Drug Profile 101

GIBH-130 - Drug Profile 106

Gln-1062 - Drug Profile 107

GTC-6000 - Drug Profile 110

gugulipid - Drug Profile 111

HOB-075 - Drug Profile 112

HTL-18318 - Drug Profile 113

intepirdine - Drug Profile 114

INV-331 - Drug Profile 117

IRL-752 - Drug Profile 118

IW-6463 - Drug Profile 119

landipirdine - Drug Profile 120

levetiracetam - Drug Profile 122

LUAF-20513 - Drug Profile 124

MM-201 - Drug Profile 125

Monoclonal Antibodies for Alzheimer’s Disease and Vascular Dementia - Drug Profile 126

Monoclonal Antibodies to Inhibit SORT1 for Alzheimer's Disease and Dementia - Drug Profile 127

Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 128

Monoclonal Antibody to Inhibit Tau for Central Nervous System Disorders - Drug Profile 129

monosodium luminol - Drug Profile 130

NAT - Drug Profile 132

nelotanserin - Drug Profile 133

Neurostem - Drug Profile 135

NI-205 - Drug Profile 137

NI-308 - Drug Profile 138

NNC-269100 - Drug Profile 139

NP-001 - Drug Profile 140

NPT100-18A - Drug Profile 143

NXN-413 - Drug Profile 144

NXN-613 - Drug Profile 145

ORY-2001 - Drug Profile 146

PAM-43 - Drug Profile 149

PBT-434 - Drug Profile 150

PD-2015 - Drug Profile 152

PD-2024 - Drug Profile 153

PD-2244 - Drug Profile 154

Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 155

PST-900 - Drug Profile 156

rivastigmine - Drug Profile 157

salicylamine - Drug Profile 158

SGE-201 - Drug Profile 159

SIN-1502 - Drug Profile 160

Small Molecule for Vascular Dementia - Drug Profile 161

Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 162

Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 163

Small Molecule to Agonize Dopamine D1 Receptor for Dementia Associated with Alzheimer's Disease - Drug Profile 164

Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 165

Small Molecule to Inhibit TNF-Alpha for CNS Disorders - Drug Profile 166

Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 167

Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile 168

Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Central Nervous System - Drug Profile 169

Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile 170

SND-14 - Drug Profile 171

Stem Cell Therapy for Dementia Associated with Alzheimer's Disease - Drug Profile 172

SUVNI-1307014 - Drug Profile 174

SUVNI-1312004 - Drug Profile 175

Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile 176

TAK-070 - Drug Profile 177

TauC-3 - Drug Profile 178

tolfenamic acid - Drug Profile 180

TPI-287 - Drug Profile 181

TRx-0237 - Drug Profile 185

UE-2343 - Drug Profile 189

VYTAU-01 - Drug Profile 192

WIB-1001C - Drug Profile 193

zonisamide - Drug Profile 194

Dementia - Dormant Projects 196

Dementia - Discontinued Products 200

Dementia - Product Development Milestones 201

Featured News & Press Releases 201

Appendix 212

Methodology 212

Coverage 212

Secondary Research 212

Primary Research 212

Expert Panel Validation 212

Contact Us 212

Disclaimer 213

List of Tables

List of Tables

Number of Products under Development for Dementia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Dementia – Pipeline by Acorda Therapeutics Inc, H1 2017

Dementia – Pipeline by Actinogen Medical Ltd, H1 2017

Dementia – Pipeline by Adamas Pharmaceuticals Inc, H1 2017

Dementia – Pipeline by AgeneBio Inc, H1 2017

Dementia – Pipeline by Alector LLC, H1 2017

Dementia – Pipeline by Allergan Plc, H1 2017

Dementia – Pipeline by AlzProtect SAS, H1 2017

Dementia – Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Dementia – Pipeline by Anavex Life Sciences Corp, H1 2017

Dementia – Pipeline by Asceneuron SA, H1 2017

Dementia – Pipeline by Axon Neuroscience SE, H1 2017

Dementia – Pipeline by Axovant Sciences Ltd., H1 2017

Dementia – Pipeline by BioArtic AB, H1 2017

Dementia – Pipeline by Biogen Inc, H1 2017

Dementia – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Dementia – Pipeline by Cortice Biosciences Inc, H1 2017

Dementia – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Dementia – Pipeline by Echo Pharmaceuticals BV, H1 2017

Dementia – Pipeline by Eisai Co Ltd, H1 2017

Dementia – Pipeline by Eli Lilly and Company, H1 2017

Dementia – Pipeline by H. Lundbeck A/S, H1 2017

Dementia – Pipeline by Heptares Therapeutics Ltd, H1 2017

Dementia – Pipeline by HSRx Group, H1 2017

Dementia – Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017

Dementia – Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017

Dementia – Pipeline by Immungenetics AG, H1 2017

Dementia – Pipeline by ImStar Therapeutics Inc, H1 2017

Dementia – Pipeline by Integrative Research Laboratories Sweden AB, H1 2017

Dementia – Pipeline by Intellect Neurosciences Inc, H1 2017

Dementia – Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Dementia – Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Dementia – Pipeline by M3 Biotechnology Inc, H1 2017

Dementia – Pipeline by MediPost Co Ltd, H1 2017

Dementia – Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017

Dementia – Pipeline by Neurimmune Holding AG, H1 2017

Dementia – Pipeline by Neuropore Therapies Inc, H1 2017

Dementia – Pipeline by NsGene A/S, H1 2017

Dementia – Pipeline by Oryzon Genomics SA, H1 2017

Dementia – Pipeline by P2D Bioscience, H1 2017

Dementia – Pipeline by Pacific Northwest Biotechnology LLC, H1 2017

Dementia – Pipeline by Pharmasum Therapeutics AS, H1 2017

Dementia – Pipeline by Prana Biotechnology Ltd, H1 2017

Dementia – Pipeline by Sage Therapeutics Inc, H1 2017

Dementia – Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017

Dementia – Pipeline by Stelic Institute & Co Inc, H1 2017

Dementia – Pipeline by Stemedica Cell Technologies Inc, H1 2017

Dementia – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Dementia – Pipeline by Suven Life Sciences Ltd, H1 2017

Dementia – Pipeline by Sylentis SAU, H1 2017

Dementia – Pipeline by TauRx Therapeutics Ltd, H1 2017

Dementia – Pipeline by Voyager Therapeutics Inc, H1 2017

Dementia – Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017

Dementia – Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017

Dementia – Dormant Projects, H1 2017

Dementia – Dormant Projects, H1 2017 (Contd..1), H1 2017

Dementia – Dormant Projects, H1 2017 (Contd..2), H1 2017

Dementia – Dormant Projects, H1 2017 (Contd..3), H1 2017

Dementia – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Dementia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports